Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.
CONCLUSIONS: Addition of rivaroxaban to the anti-platelet regimen was effective in patients with coronary artery disease, but the safety outcomes were doubtful. Further future trials will be able to completely solve this issue.
PMID: 29720261 [PubMed - in process]
Source: BMC Pharmacology and Toxicology - Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research
More News: Bleeding | Cardiology | Cardiovascular | Databases & Libraries | Drugs & Pharmacology | Heart | Heart Attack | Hemorrhagic Stroke | Stroke | Thrombosis | Toxicology